「ex」の検索結果
129件：31～35件目を表示
-
R&D Pipeline | Research & Development | SENJU Pharmaceutica
PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) PranoprofeninflammationApplication under review (Vietnam) SJP-0135GlaucomaApproval（Japan） SJP-0132Dry ey
http://www.senju.co.jp/english/rd/pipeline.html -
タリムス点眼液0.1%
2 ,14 ,15 ,16 ,18 ,19 ,26a ） - 5,19-Dihydroxy-3- ｛ （1 ） -2- ［ （1 ,3 ,4 ） -4-hydroxy- 3-methoxycyclohexyl]-1-methylethenyl｝ -14,16- dimethoxy-4,10,12,18-tetramethyl-8- （prop-2-en-1-yl） - 15,19-epoxy-5,...
https://www.senju.co.jp/system/files/product_other_file/2023-01/Talymus_202302_C2.pdf -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
lt Lake City, Utah, United States of America Effects of a novel TRPV1 antagonist, SJP-0132, on CCL5 expression in corneal epithelial cells Yuya Atsumi, Toshizo Sato, Atsuhiro Kanda ARVO 2025 開催日：2025年...
http://www.senju.co.jp/english/rd/society/ -
n, were observed at similar frequencies with the new formulation. Therefore, the new formulation is expected to contribute to improved adherence among glaucoma patients while ensuring safe and reliabl...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904.pdf -
Research and Development System | Research & Development | SENJU Pharmaceutica
int research and industry-academia joint research, and tackles research and development through a flexible concept without adhering to a conventional framework or stereotypes. Looking at the future an...
http://www.senju.co.jp/english/rd/about/